Literature DB >> 19031771

[Application of Stata software to test heterogeneity in meta-analysis method].

Dan Wang1, Zhen-yun Mou, Jun-xia Zhai, Hong-xia Zong, Xiao-dong Zhao.   

Abstract

To introduce the application of Stata software to heterogeneity test in meta-analysis. A data set was set up according to the example in the study, and the corresponding commands of the methods in Stata 9 software were applied to test the example. The methods used were Q-test and I2 statistic attached to the fixed effect model forest plot, H statistic and Galbraith plot. The existence of the heterogeneity among studies could be detected by Q-test and H statistic and the degree of the heterogeneity could be detected by I2 statistic. The outliers which were the sources of the heterogeneity could be spotted from the Galbraith plot. Heterogeneity test in meta-analysis can be completed by the four methods in Stata software simply and quickly. H and I2 statistics are more robust, and the outliers of the heterogeneity can be clearly seen in the Galbraith plot among the four methods.

Mesh:

Year:  2008        PMID: 19031771

Source DB:  PubMed          Journal:  Zhonghua Liu Xing Bing Xue Za Zhi        ISSN: 0254-6450


  20 in total

Review 1.  Pegylated liposomal doxorubicin in the management of ovarian cancer: a systematic review and metaanalysis of randomized trials.

Authors:  Nicoletta Staropoli; Domenico Ciliberto; Cirino Botta; Lucia Fiorillo; Anna Grimaldi; Stefania Lama; Michele Caraglia; Angela Salvino; Pierfrancesco Tassone; Pierosandro Tagliaferri
Journal:  Cancer Biol Ther       Date:  2014-03-21       Impact factor: 4.742

2.  MiR-16 family as potential diagnostic biomarkers for cancer: a systematic review and meta-analysis.

Authors:  Jianxiong Cui
Journal:  Int J Clin Exp Med       Date:  2015-02-15

3.  A systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: Evidence does not translate?

Authors:  Domenico Ciliberto; Nicoletta Staropoli; Francesca Caglioti; Simona Gualtieri; Lucia Fiorillo; Silvia Chiellino; Antonina Maria De Angelis; Francesco Mendicino; Cirino Botta; Michele Caraglia; Pierfrancesco Tassone; Pierosandro Tagliaferri
Journal:  Cancer Biol Ther       Date:  2015-06-10       Impact factor: 4.742

4.  Is CD147 a New Biomarker Reflecting Histological Malignancy of Gliomas?

Authors:  Xiangyi Kong; Yu Wang; Congxin Dai; Wenbin Ma; Renzhi Wang
Journal:  Mol Neurobiol       Date:  2016-05-20       Impact factor: 5.590

5.  Diagnostic value of circulating microRNAs for hepatocellular carcinoma.

Authors:  Yanping Yang; Rui Zhu
Journal:  Mol Biol Rep       Date:  2014-07-17       Impact factor: 2.316

6.  Association between Cytotoxic T-lymphocyte antigen 4 (CTLA-4) +49 G>A (rs231775) polymorphism and esophageal cancer: from a case-control study to a meta-analysis.

Authors:  Chao Liu; Yafeng Wang; Heping Jiang; Weifeng Tang; Shuchen Chen; Mingqiang Kang; Changqing Dong; Haiyong Gu
Journal:  Int J Clin Exp Med       Date:  2015-10-15

7.  CD105 Over-expression Is Associated with Higher WHO Grades for Gliomas.

Authors:  Xiangyi Kong; Yu Wang; Shuai Liu; Bing Xing; Yi Yang; Yongning Li; Zuyuan Ren; Changbao Su; Wenbin Ma; Renzhi Wang
Journal:  Mol Neurobiol       Date:  2016-02-16       Impact factor: 5.590

8.  Polymorphisms in the intercellular adhesion molecule 1 gene and cancer risk: a meta-analysis.

Authors:  Weifeng Tang; Yafeng Wang; Yuanmei Chen; Haiyong Gu; Shuchen Chen; Mingqiang Kang
Journal:  Int J Clin Exp Med       Date:  2015-08-15

9.  XRCC1 polymorphisms and risk of colorectal cancer: a meta-analysis.

Authors:  Bin Wang; Dan Wang; Gang Huang; Chao Zhang; Dong-hua Xu; Weiping Zhou
Journal:  Int J Colorectal Dis       Date:  2009-12-24       Impact factor: 2.571

Review 10.  Diagnostic accuracy of circulating tumor cells detection in gastric cancer: systematic review and meta-analysis.

Authors:  Lanhua Tang; Shushan Zhao; Wei Liu; Nicholas F Parchim; Jin Huang; Youhong Tang; Pingping Gan; Meizuo Zhong
Journal:  BMC Cancer       Date:  2013-06-27       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.